Western blot and immunofluorescence (IF) assays revealed that PRMT5 knockdown elevated γ‐H2AX levels in CRC cells following CPT‐11 treatment (Figure 2J–N; Figure S3E, Supporting Information). This evidence concerns the gene H2AX and colorectal carcinoma.